ClinConnect ClinConnect Logo

Main Menu

Search for Trials
For HCPs
For Industry
Blog
Contact Us
Dark Mode
Log in Sign up
Search / Trial NCT03330015

Patient's Experience and Choice Between Investigations for Endometrial Cancer in Postmenopausal Bleeding

Launched by CHINESE UNIVERSITY OF HONG KONG · Oct 30, 2017

Download PDF Apply for Trial

Trial Information

Current as of April 25, 2025

Completed

Keywords

Postmenopausal Bleeding Endometrial Cancer Patient's Experience Patient's Choice

ClinConnect Summary

Endometrial cancer is the most common malignancy of the female genital tract in Hong Kong. It is estimated that around 10% of women experience postmenopausal bleeding. Around 90% of women with endometrial cancer initially presented with postmenopausal bleeding (PMB). The aim in the evaluation of PMB is to exclude underlying malignancy. Clinical tests to evaluate the endometrium include transvaginal ultrasound scanning (TVS) to measure endometrial thickness (ET), endometrial biopsy or sampling (ES), saline infusion sonography, and hysteroscopy. TVS ET or ES has been recommended as the first-...

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • • postmenopausal woman
  • • referrals for the symptom of PMB
  • Exclusion Criteria:
  • • dementia
  • • mental retardation

Trial Officials

Wen Ying Fung

Principal Investigator

Chinese University of Hong Kong

About Chinese University Of Hong Kong

The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.

Locations

Hong Kong, , Hong Kong

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials